Q4 2023 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Alembic Pharmaceuticals Limited Conference Call on discussion on company's Q4 and annual FY '23 Audited Financial Results. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. R.K. Baheti, Director of Finance and CFO. Thank you, and over to you, sir.
Thank you. Good evening, everyone. Thank you all for joining the Fourth Quarter Annual Regional Conference Call. Let me start with the financials, and there are a few nondating or one-offs, which I'll try to explain. And then, of course, we'll take your questions.
So financials first. During the quarter, the total revenue is INR 1,406 crores, EBITDA is INR 205 crores, net property is INR 153 crores. EBITDA margin for the quarter is 14.5% -- for the full year FY '20, revenue is INR 5,643 crores, INR 653 crores, EBITDA is INR 680 crores and net profit is INR 342 crores.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
